|
Published by: Kalorama Information
Published: Jan. 1, 1996 - 258 Pages Now 50% off the original sale price of $3,250.
Table of Contents
Chapter 1: Executive Summary
- Scope and Methodology
- Trends Affecting the Market
- The Urgent Need for Antivirals
- The Forecast for Vaccines, 1996‑2020
- The Impact of Managed Care on Drug Manufacturers
- Diversification
- Licensing Arrangements
- Mergers
- Pharmacy Benefit Plans
- Probationary Alliances
- Vertical Integration
- Virtual Integration
- Industry Structure and Leading Competitors
- New Arrangements to Meet New Challenges
- Consolidated Alliances
- The InterCompany Collaboration for AIDS Drug Development
- Changes Among Leading Antiviral Competitors
- The U.S. Market
- Notes on the Data
- Size of the Market
Chapter 2: Introduction to Viral Diseases
- Scope and Methodology
- Overview of Selected Viral Diseases
- AIDS and HIV Infection
- The Discovery of HIV
- Description of HIV
- Pathology
- Epidemiology
- Transmission
- Characteristics of Infected Populations
- Signs and Symptoms
- Worldwide Statistics
- United States Statistics
- The Expanded Definition of AIDS
- Survival Statistics
- Cost of Treating HIV Infection and AIDS [4]
- Dengue Fever
- Genital Warts
- Hepatitis
- Hepatitis A
- Hepatitis B
- Hepatitis C
- Hepatitis D
- Hepatitis E
- Hepatitis G
- Hepatitis X
- Newly Discovered Strains of Hepatitis
- Herpesviruses
- Cytomegalovirus
- Epstein‑Barr Syndrome
- Herpes Simplex I
- Herpes Simplex II
- Herpes Zoster
- Human B19 Parvovirus
- Influenza
- Measles, Mumps, and Rubella
- Poliomyelitis
- Respiratory Syncytial Virus
- Rare and Emerging Viral Disease Threats
- Ebola Virus
- Hantavirus
- Junin Virus
- Lassa Virus
- Machupo Virus
- Marburg Virus
- Oropouche Virus
- Rift Valley Fever
- Sabia Virus
- Is There (Another) Coming Plague?
Chapter 3: Currently Available Antiviral Products
- Introduction
- AIDS and HIV Therapeutics
- New Product Approvals of 1994 and 1995
- Epivir
- Cytovene
- Foscavir
- Hivid
- Interferons
- Intron A
- Roferon‑A
- Invirase
- Retrovir
- Videx
- Zerit
- Hepatitis Products
- Therapeutics
- Immune Globulins
- Intron A
- Vaccines
- Engerix‑B and Recombivax HB
- Havrix
- Herpesvirus Products
- Therapeutics
- Alferon N Injection
- Famvir
- Valtrex
- Zovirax
- Vaccines
- Influenza Products
- Therapeutics
- Amantadine Hydrochloride and Rimantadine Hydrochloride
- Flumadine
- Symmetrel
- Vaccines
- Measles-Mumps-Rubella Combination Vaccines
- Polio Vaccines
- Respiratory Syncytial Virus Products
- Rare Disease and Other Products
Chapter 4: Antiviral Products in Development
- Notes on the Data
- Leading Antiviral Technologies
- Gene Therapy
- Vaccines
- First-Generation or Traditional Vaccines
- Second-Generation Vaccines
- AIDS and HIV Products
- Antivirals
- Apoptosis Agents
- Description
- Development of Anti‑Apoptosis Agent CoQ10
- Combination Therapy with Existing Products
- Gene Therapy
- Adoptive Transfer
- Antisense
- Direct Killing
- The Gene Gun
- Ribozymes
- Nucleotide‑Based Drugs
- Protease Inhibitors
- Crixivan
- Palinavir
- Ritonavir
- Viracept
- VX‑478
- Other Protease Inhibitors in Development
- Reverse Transcriptase Inhibitors
- Vaccines
- Vaccine Development Strategies
- Live, Killed, and Genetically Engineered Viruses
- Genetically Engineered AIDS Vaccines
- Phases of AIDS Vaccine Trials
- AIDS Vaccines in Clinical Trials
- gp120 Vaccines
- gp160 Vaccines
- HIV‑Immunogen
- VaxSyn
- Other Vaccines
- CD26
- HGP‑30
- p24 Vaccine
- RP400c Vaccine
- Targets for Future AIDS Vaccine Design
- Cytomegalovirus Infection
- Dengue Fever
- Genital Warts
- Hepatitis
- Hepatitis A
- Hepatitis B
- Hepatitis C
- Hepatitis D
- Hepatitis E
- Hepatitis X
- Herpesviruses
- Therapeutics
- New Indications for Famvir
- Trials Comparing Famvir and Valaciclovir in the Treatment of HSV Infections
- Other Herpesvirus Treatments in Development
- Vaccines
- Products in Development
- Survey of Acceptance of a Genital Herpes Vaccine
- Human B19 Parvovirus
- Influenza
- Respiratory Syncytial Virus
- Rare Disease and Other Products
Chapter 5: Issues and Trends
- Market Trends
- The Urgent Need for Antivirals
- Prophylactic Vaccines
- Government Support of Antiviral Research
- Patent Expirations
- Protease Inhibitors—Will High Production Costs Force High Prices?
- The Forecast for Vaccines, 1996‑2020
- Increasing Emphasis on Immunization Worldwide
- New Vaccine Products Expand the Market
- Trends in the European Antiviral Vaccines Market
- Cost versus Efficiency of the Varicella Vaccine
- Industry Trends
- The Impact of Managed Care on Drug Manufacturers
- Pricing
- Diversification
- Licensing Arrangements
- Mergers
- Pharmacy Benefit Plans
- Probationary Alliances
- Vertical Integration
- Virtual Integration
- Patent Disputes
- Consolidated Alliances
- The InterCompany Collaboration for AIDS Drug Development
- Strategies for Successfully Developing Gene Therapy Products
- The Multi‑Vector Approach
- Genomics
- Investors Bullish on Genomics
- The Gene Club
- Overseas Launch
- Barriers to Entry in the Vaccine Market
- Regulatory Trends
- Factors Affecting New Anti‑AIDS Drug Development
- The United States Food and Drug Administration
- New FDA Initiatives to Expedite Approval of Promising Drugs
- Expedited Review for Drugs to Treat Life‑threatening Diseases
- Treatment-Use Applications
- Parallel Track Policy
- Emergency or Compassionate Use Protocols
- Patent Protection for Gene Therapy
- Technology Trends
- Development of an AIDS Vaccine—A Road Fraught With Adversity
- Vaccines Against Viral Strains of HIV That No Longer Exist
- Preventive or Therapeutic Treatment
- Novel Delivery Systems
- Liposomes
- Microspheres
- Nanoparticles
- Leading Competitors in the Antivirals Market—Today and Tomorrow
Chapter 6: The U.S. Market
- Scope and Methodology
- Notes on the Data
- Antiviral Therapeutics and Vaccines
- AIDS and HIV Therapeutics
- Size of the Market
- Usage Trends
- Hepatitis Products
- Therapeutics
- Size of the Market
- Market Composition
- Vaccines
- Size of the Market
- Usage Trends
- Herpesvirus Products
- Therapeutics
- Size of the Market
- Usage Trends
- Vaccines
- Size of the Market
- Influenza Products
- Therapeutics
- Size of the Market
- Vaccines
- Size of the Market
- Usage Trends
- Measles-Mumps-Rubella Combination Vaccines
- Oral Polio Vaccines
- Respiratory Syncytial Virus Therapeutics
- Rare Disease and Other Products
Chapter 7: Corporate Profiles
- Amgen, Inc.
- History and Lines of Business
- Financial Information
- Products
- Research and Development
- Corporate Strategies
- Biogen, Inc.
- Organization and Lines of Business
- Financial Information
- Products
- Research and Development
- Corporate Strategies
- Bristol‑Myers Squibb Company
- History and Lines of Business
- Financial Information
- Products
- Research and Development
- Corporate Strategies
- E.I. Du Pont de Nemours
- Organization and Lines of Business
- Financial Information
- Products
- Research and Development
- Corporate Strategies
- Genelabs Technologies, Inc.
- History and Lines of Business
- Financial Information
- Products
- Research and Development
- Corporate Strategies
- Genentech, Inc.
- History and Lines of Business
- Financial Information
- Products
- Research and Development
- Corporate Strategies
- Gilead Sciences, Inc.
- Organization and Lines of Business
- Financial Information
- Products
- Research and Development
- Corporate Strategies
- Glaxo Wellcome Company
- History and Lines of Business
- Financial Information
- Products
- Research and Development
- Corporate Strategies
- ICN Pharmaceuticals, Inc.
- Organization and Lines of Business
- Financial Information
- Products
- Research and Development
- Corporate Strategies
- Interferon Sciences, Inc.
- History and Lines of Business
- Financial Information
- Products
- Research and Development
- Corporate Strategies
- Isis Pharmaceuticals, Inc.
- History and Lines of Business
- Financial Information
- Products
- Research and Development
- Corporate Strategies
- MedImmune, Inc.
- History and Lines of Business
- Financial Information
- Products
- Research and Development
- Corporate Strategies
- Merck & Company, Inc.
- History and Lines of Business
- Financial Information
- Products
- Research and Development
- Corporate Strategies
- MicroProbe Corporation
- History and Lines of Business
- Financial Information
- Products
- Research and Development
- Corporate Strategies
- Protein Design Labs, Inc.
- History and Lines of Business
- Financial Information
- Products
- Research and Development
- Corporate Strategies
- Roche Holding Limited
- History and Lines of Business
- Financial Information
- Products
- Research and Development
- Corporate Strategies
- Shaman Pharmaceuticals
- History and Lines of Business
- Financial Information
- Products
- Research and Development
- Corporate Strategies
- SmithKline Beecham Plc
- History and Lines of Business
- Financial Information
- Products
- Research and Development
- Corporate Strategies
- The Upjohn Company
- Organization and Lines of Business
- Financial Information
- Products
- Research and Development
- Corporate Strategies
- Verex Laboratories, Inc
- History and Lines of Business
- Financial Information
- Products
- Research and Development
- Corporate Strategies
- Viragen, Inc.
- History and Lines of Business
- Financial Information
- Products
- Research and Development
- Corporate Strategies
- Warner Chilcott Laboratories
- History and Lines of Business
- Financial Information
- Products
- Corporate Strategies
- Wyeth‑Ayerst Laboratories
- History and Lines of Business
- Financial Information
- Products
- Research and Development
- Corporate Strategies
Appendix A: Commonly Used Antiviral Products
Appendix B: Company Names and Addresses
AbstractThis report from Kalorama Information examines the burgeoning antiviral market, and provides a comprehensive analysis of both therapeutics and vaccines: AIDS and HIV therapeutics; hepatitis therapeutics and vaccines; influenza therapeutics and vaccines; mumps, measles, and rubella vaccines; polio vaccines; respiratory syncytial virus therapeutics; and products used to treat rare diseases. Offers historical information for the past 5 years and forecasts for the next 5 years. Profiles include established and emerging pharmaceutical manufacturers.
Get Full Details About This Report >>
|
